Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Makes It Official With Basaglar Approval For Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

Eli Lilly/Boehringer Ingelheim’s insulin glargine product had already received tentative approval from FDA. The final approval clears the way for an eventual copycat version of Sanofi’s Lantus.

You may also be interested in...



Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.

Biologics Transition Plan From US FDA Will Consider Therapeutic Equivalence Ratings

While industry awaits formal guidance ahead of March 2020 transition deadline for certain protein products, FDA's Christl says plan will take into account therapeutic equivalence ratings when deciding whether products are 'deemed' licensed as full biologic applications or biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel